Ocugen also reported updated results from a phase 1 trial, which showed that ellipsoid zone (EZ) loss – which results in the ...
An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...
Geographic atrophy is a growing worldwide health issue, with approximately 8 million patients impacted, according to a ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...
Clinical Trials Arena on MSN
Ocugen sets sights on Phase III after GA gene therapy win
GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The "Geographic Atrophy Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The global ...
Maybe you’ve noticed that you can no longer see your friends and family clearly. Or perhaps it’s becoming increasingly hard — if not impossible — to drive yourself to your favorite restaurant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback